Late-stage Cimzia trial for RA hits endpoints

UCB says that a late-stage trial of Cimzia in combination with methotrexate for rheumatoid arthritis prevented significant joint damage in comparison with a placebo. The study "achieved its co-primary endpoint, the inhibition of progression of structural damage," said the company in a statement. "The study also showed that in both active treatment arms Cimzia improved the signs and symptoms of rheumatoid arthritis to a clinically statistically significantly greater degree than the placebo arm in patients who had inadequately responded to methotrexate alone." More Phase III data will be released over the course of the year.

- check out the release [1] on the results
- here's the AFX report [2] on the trial

Related Articles:
UCB to acquire Schwarz in latest buyout deal. Report [3]
UCB licenses Immunomedics drug in $203M pact. Report [4]
UCB submits BLA for Cimzia. Report [5]